Immunotherapy in Melanoma | Specialty

Dr. Sullivan on Sequencing Targeted Therapy and Immunotherapy in Melanoma

January 13th 2021

Ryan Sullivan, MD, discusses treatment sequencing with targeted therapy and immunotherapy in melanoma.

Dr. Sznol on the Multidisciplinary Management of Immunotherapy-Associated Toxicities in Melanoma

January 11th 2021

Mario Sznol, MD, Yale Cancer Center, discusses the multidisciplinary management of toxicities associated with immunotherapy in patients with melanoma.

FDA Grants Orphan Drug Designation to PVSRIPO for Advanced Melanoma

January 11th 2021

January 11, 2021 — The FDA has granted an orphan drug designation to the novel intratumoral immunotherapy agent PVSRIPO for the treatment of patients with advanced melanoma, specifically those with stage IIIB-IV disease.

Dr. Sznol on Toxicities Associated With Immunotherapy in Melanoma

January 7th 2021

Mario Sznol, MD, discusses toxicities associated with immunotherapy in patients with melanoma.

Sznol Advocates for More Awareness of Immune-Related Toxicities in Oncology

December 14th 2020

Mario Sznol, MD, discusses the critical importance of being aware of the immune-related toxicities that could arise when treating patients with cancer, along with the best ways to manage them.

Robert Recaps a Career of Clinical Research in Melanoma

December 7th 2020

In our exclusive interview, Caroline Robert, MD, PhD, discusses her groundbreaking work on clinical trials evaluating anti–CTLA-4 and anti–PD-1 antibodies in advanced melanoma, her experiences as a researcher in France and the United States, her love of traveling, and next steps for the field.

Dr. Rapisuwon on the Frontline Treatment of Acral and Mucosal Melanoma

December 3rd 2020

Suthee Rapisuwon, MD, discusses the frontline treatment of acral and mucosal melanoma.

Hunt for Reliable Biomarkers for Immunotherapy Continues in Melanoma

November 5th 2020

Douglas B. Johnson, MD, MSCI, discusses his research examining the impact of body composition on outcomes from anti–PD-1 with or without anti–CTLA-4 therapies in melanoma and other biomarkers under exploration.

Rapisuwon Reviews Management Approaches for Advanced Noncutaneous Melanoma Subtypes

October 8th 2020

Suthee Rapisuwon, MD, reviews management strategies under exploration for mucosal, acral, and uveal melanoma.

Adjuvant Nivolumab/Ipilimumab Fails to Significantly Improve RFS in High-Risk Melanoma

October 5th 2020

The immunotherapy combination of adjuvant nivolumab and ipilimumab failed to lead to a statistically significant improvement in recurrence-free survival in the intent-to-treat population of patients with resected stage IIIB/C/D or stage IV melanoma.